Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: Trends Pharmacol Sci. 2022 Apr 19;43(6):510–521. doi: 10.1016/j.tips.2022.03.003

Figure 3.

Figure 3.

Recent examples of polymeric and small-molecule prodrugs in nanomedicine. (a) Programmed multidrug delivery by supramolecular polymeric drug conjugates. BLPNs prodrugs include an MMP-2/9-degradable GALGLPG peptide sequence, an acid-activatable tertiary amine group, and a GSH-cleavable disulfide linker. With displayed orthogonal response to MMP-2 microenvironment and intracellular acid/reduction microenvironment at the tumor sites, the BLPNs prodrugs enabled codelivery of dual immune modulators and combination immunotherapy. Adapted from [49]; copyright 2020 Wiley. (b) Cabotegravir (CAB) prodrugs modified with fatty acid esters were formulated into nanocrystals. The nanoformulated CAB prodrugs showed a year-long extended release while maintaining plasma CAB concentration above the protein-adjusted 90% inhibitory concentration (PA-IC90). Adapted from [70]; copyright 2020 Springer Nature.